Lead Product(s) : Zibotentan,Dapagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zibotentan/dapagliflozin combination leverages SGLT2 inhibition and high selectivity ETA receptor antagonism. It is being evaluated in phase 2 clinical trials for the treatment of chronic kidney disease and proteinuria.
Product Name : ZD4054
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2023
Lead Product(s) : Zibotentan,Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable